Martin Marino Buys 100,000 Shares of Microbix Biosystems (TSE:MBX) Stock

Microbix Biosystems Inc. (TSE:MBX) Director Martin Marino bought 100,000 shares of Microbix Biosystems stock in a transaction on Monday, December 22nd. The shares were purchased at an average cost of C$0.23 per share, with a total value of C$23,000.00. Following the completion of the purchase, the director directly owned 1,691,667 shares in the company, valued at C$389,083.41. This trade represents a 6.28% increase in their ownership of the stock.

Martin Marino also recently made the following trade(s):

• On Monday, December 29th, Martin Marino bought 52,500 shares of Microbix Biosystems stock. The stock was purchased at an average price of C$0.24 per share, with a total value of C$12,600.00.

Microbix Biosystems Stock Performance

MBX opened at C$0.22 on Monday. The business’s 50 day moving average is C$0.24 and its 200-day moving average is C$0.25. The stock has a market cap of C$30.54 million, a PE ratio of -13.75 and a beta of 0.03. The company has a current ratio of 7.15, a quick ratio of 5.57 and a debt-to-equity ratio of 22.61. Microbix Biosystems Inc. has a twelve month low of C$0.21 and a twelve month high of C$0.55.

Microbix Biosystems (TSE:MBX) last issued its quarterly earnings data on Thursday, December 18th. The company reported C($0.01) earnings per share (EPS) for the quarter. The business had revenue of C$3.74 million during the quarter. Microbix Biosystems had a return on equity of 12.65% and a net margin of 13.86%. On average, analysts predict that Microbix Biosystems Inc. will post 0.02 earnings per share for the current year.

Microbix Biosystems Company Profile

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.